A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer

Burmeister, B., Walpole, E., D'Arcy, N., Burmeister, E.A., Cox, S., Thomson, D.B., Harvey, J. and Smithers, B.M. (2009) A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer. Investigational New Drugs, 27 3: 275-279. doi:10.1007/s10637-008-9178-4


Author Burmeister, B.
Walpole, E.
D'Arcy, N.
Burmeister, E.A.
Cox, S.
Thomson, D.B.
Harvey, J.
Smithers, B.M.
Title A phase II trial of chemoradiation therapy with weekly oxaliplatin and protracted infusion of 5-fluorouracil for esophageal cancer
Journal name Investigational New Drugs   Check publisher's open access policy
ISSN 0167-6997
Publication date 2009-01-01
Year available 2008
Sub-type Article (original research)
DOI 10.1007/s10637-008-9178-4
Open Access Status Not yet assessed
Volume 27
Issue 3
Start page 275
End page 279
Total pages 5
Editor Rowinsky, E.K.
Place of publication USA
Publisher Springer New York LLC
Language eng
Subject C1
920102 Cancer and Related Disorders
1112 Oncology and Carcinogenesis
Abstract Summary Background Chemoradiation therapy using regimens containing cisplatin and 5-fluorouracil are most commonly used for inoperable cancer of the esophagus. Cisplatin is relatively toxic and is not suitable for many patients. Little data exists using platinum analogues together with protracted infusion 5-fluorouracil and radiation therapy in the curative setting. Methods Fourteen patients with localised oesophageal cancer suitable for curative chemoradiation therapy registered on the study. Chemotherapy consisted of 5-fluorouracil 225 mg/m2 daily throughout radiation therapy, with oxaliplatin 60 mg/m2 weekly. The radiation dose was 56 to 60 Gy in 28 to 30 fractions. Results The median age of the patients was 70.5 years. Therapy was associated with excessive grade 3 and 4 non-hematologic toxicity. There was one treatment related death. The median progression-free survival was 31.5 months and median overall survival 32.6 months. Six patients achieved a prolonged complete endoscopic and radiological response. Conclusions Although weekly oxaliplatin in combination with infusional 5 fluorouracil produces durable remissions in esophageal cancer, the regimen used in this trial was not acceptable for routine use. Future protocols should incorporate lower chemotherapy doses.
Keyword Oncology
Pharmacology & Pharmacy
Oncology
Pharmacology & Pharmacy
ONCOLOGY
PHARMACOLOGY & PHARMACY
Q-Index Code C1
Q-Index Status Confirmed Code
Grant ID L_8794
Institutional Status UQ
Additional Notes Published online: 8 October 2008 adn in print Volume 27, Number 3 / June, 2009

Document type: Journal Article
Sub-type: Article (original research)
Collections: 2009 Higher Education Research Data Collection
School of Medicine Publications
 
Versions
Version Filter Type
Citation counts: TR Web of Science Citation Count  Cited 10 times in Thomson Reuters Web of Science Article | Citations
Scopus Citation Count Cited 12 times in Scopus Article | Citations
Google Scholar Search Google Scholar
Created: Mon, 06 Apr 2009, 21:37:13 EST by Denise Wilson on behalf of School of Medicine